Cargando…
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new op...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063116/ https://www.ncbi.nlm.nih.gov/pubmed/21448449 http://dx.doi.org/10.2147/DDDT.S13029 |